APO-TRAVOPROST 0.003 %
TRAVOPROST : 0.003 % · DIN 02489775 · APOTEX INC
Health Canada status: APPROVED
What is APO-TRAVOPROST?
APO-TRAVOPROST 0.003 % contains TRAVOPROST : 0.003 %. It is listed in the Health Canada Drug Product Database under DIN 02489775, held by APOTEX INC, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as approved, status dated 01-Jun-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02489775 |
|---|---|
| Brand name | APO-TRAVOPROST |
| Generic / active ingredient | TRAVOPROST : 0.003 % |
| Manufacturer | APOTEX INC |
| Strength | 0.003 % |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01EE04 TRAVOPROST |
| AHFS class | 84:80.00 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 01-Jun-2020 |
| Original market date | 2020-02-07 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code S01EE04 TRAVOPROST. 4 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| IZBA | 0.003 % | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02457997 |
| JAMP TRAVOPROST Z | 0.004 % | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02548089 |
| SANDOZ TRAVOPROST | 0.004 % | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02413167 |
| TRAVATAN Z | 0.004 % | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02318008 |
| APO-TRAVOPROST Z | 0.004 % | SOLUTION | APOTEX INC | DORMANT | DIN 02415739 |
| MYLAN-TRAVOPROST Z | 0.004 % | SOLUTION | MYLAN PHARMACEUTICALS ULC | CANCELLED PRE MARKET | DIN 02428121 |
| PMS-TRAVOPROST Z | 0.004 % | SOLUTION | PHARMASCIENCE INC | CANCELLED PRE MARKET | DIN 02424479 |
| TEVA-TRAVOPROST Z OPHTHALMIC SOLUTION | 0.004 % | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02412063 |
| TRAVATAN | 0.004 % | SOLUTION | ALCON CANADA INC | CANCELLED POST MARKET | DIN 02244896 |
Who else supplies TRAVOPROST worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRAVOPROST appears in 64 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.